Global GLP-1 pipeline

Registry estimate for the phase 3 comparison against tirzepatide in adults with obesity.

The registry estimates a December start for the trial in adults with obesity without type 2 diabetes.

Novo Nordisk expects a decision in Q4 2026. The outcome and exact date are pending.

Registry estimate for the phase 3 weight-management trial without type 2 diabetes.

Registry estimate for a phase 3 study in people with type 2 diabetes who fast during Ramadan. It lists seven UAE sites, including Emirates Hospital Dubai and Dubai Hospital.

Registry estimate for the phase 3 injectable programme in adults with obesity or overweight and a related condition.

Estimated primary completion for NCT06972459.

Registry estimate for the phase 3 oral weight-management trial.

The Emirates Drug Establishment announced a new indication for adults with type 2 diabetes.

The trial studies the combination in adults with obesity or overweight and type 2 diabetes.

Viking announced two SUNRISE trials for the daily oral formulation.

The paper reports results for 4 mg, 9 mg and 12 mg in adults with obesity or overweight and type 2 diabetes.

The Korean regulator lists authorization for eligible adults with obesity or overweight without diabetes.

Lilly reported results for the investigational combination of eloralintide and tirzepatide against tirzepatide 15 mg.

Novo reported the trial underway by its September update. It studies cagrilintide 2.4 mg with semaglutide 7.2 mg.

Phase 3 trial of oral zenagamtide for weight management.

The FDA updated the label to cover reduction of major cardiovascular events in adults with type 2 diabetes at high risk.

Novo Nordisk reported that the FDA accepted a filing to add data from the ESSENCE study of metabolic dysfunction-associated steatohepatitis (MASH) to the oral Wegovy 25 mg label. The company expected a decision in Q1 2027.

Ireland’s medicines regulator lists the centrally authorised 7.2 mg pre-filled pen.

France’s public medicines database lists the EU marketing authorisation for Wegovy 25 mg tablets.

The phase 3 publication reports 76-week outcomes for 3.6 mg, 6.0 mg and placebo.

The Emirates Drug Establishment announced oral semaglutide approval for weight management and cardiovascular risk reduction in eligible adults.

Lilly’s SEC filing places the FDA submission in the second quarter of 2026.

This Ramadan study enrolled people with type 2 diabetes. The registry lists UAE sites including Tawam Hospital, Dubai Hospital and Emirates Hospital Dubai.

The MHRA authorized the 7.2 mg single-dose pen for adults with obesity.

The Emirates Drug Establishment announced orforglipron’s weight-management approval.

The FDA approved orforglipron tablets for long-term weight reduction and maintenance in eligible adults.

The FDA approved the 7.2 mg injection for weight loss and long-term weight maintenance in certain adults.

Sciwind reported NMPA approval of weekly ecnoglutide for eligible adults with obesity or overweight.

The MHRA authorized the higher weekly dose for eligible adults with obesity. The single-dose pen was authorized separately.

The FDA approved the oral formulation for weight management and cardiovascular risk reduction in eligible adults.

The filing covers the cagrilintide 2.4 mg and semaglutide 2.4 mg combination.

Innovent announced that China’s Center for Drug Evaluation accepted the 9 mg supplementary application for review. The application was based on GLORY-2.

China’s National Medical Products Administration approved mazdutide for chronic weight management in eligible adults.

The EU label added weight management for eligible children aged 6 to 11 with obesity.

The FDA approved tirzepatide under the Mounjaro brand for glycaemic control in adults with type 2 diabetes.

The FDA approved weekly semaglutide 2.4 mg for chronic weight management in eligible adults.